Physician profile
Albert Ferrara
NPI 1205940434
$8,421.64
in general payments reported to CMS, 2019-2025
51 companies · $753 in 2025
The $753 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $1,073 · 2021: $1,385 · 2022: $1,499 · 2023: $1,218 · 2024: $1,245 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,216.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,132.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,075.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,073.73 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $843.47 | 2020-2025 | |
| Lilly USA, LLC | $536.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $440.97 | 2019-2025 | |
| Amarin Pharma, INC. | $301.54 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $273.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $250.15 | 2019-2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.23 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $163.71 | 2019-2023 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.83 | 2021-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $154.71 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $148.87 | 2021-2024 | Xarelto |
| Exact Sciences Corporation | $137.23 | 2023-2024 | Cologuard Collection Kit |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $127.60 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $117.66 | 2022-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $102.93 | 2019-2023 | |
| Sanofi Pasteur INC. | $99.82 | 2019-2024 | |
| Allergan, INC. | $82.39 | 2019-2020 | |
| Gilead Sciences, INC. | $79.85 | 2019-2021 | |
| Esperion Therapeutics, INC. | $63.32 | 2020-2023 | Nexletol |
| Phathom Pharmaceuticals, INC. | $58.86 | 2024 | Voquezna |
| Hikma Pharmaceuticals USA | $53.60 | 2020 | |
| Seqirus USA INC | $51.22 | 2019-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Eisai INC. | $45.86 | 2023-2024 | |
| Supernus Pharmaceuticals, INC. | $44.50 | 2019-2021 | |
| Genentech USA, INC. | $43.73 | 2020-2021 | |
| Bardy Diagnostics, INC. | $41.59 | 2020-2022 | |
| Inspire Medical Systems, INC. | $34.90 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $34.06 | 2025 | Keveyis |
| E.R. Squibb & Sons, L.L.C. | $32.69 | 2019-2024 | Eliquis |
| Genzyme Corporation | $30.37 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.21 | 2023 | |
| Ardelyx, INC. | $28.49 | 2023 | Ibsrela |
| Phadia US INC. | $27.40 | 2021-2024 | Immunocap |
| Novavax INC | $26.39 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Linus Health, INC. | $26.18 | 2023 | |
| Dynavax Technologies Corporation | $25.08 | 2023 | Heplisav-B |
| Corcept Therapeutics | $24.00 | 2025 | Korlym |
| Dexcom, INC. | $22.58 | 2022 | |
| Ibsa Pharma INC. | $22.01 | 2022 | |
| Bausch Health US, LLC | $20.38 | 2022 | |
| Teleflex LLC | $20.19 | 2022 | |
| Axsome Therapeutics, INC. | $19.48 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.16 | 2022 | |
| Shield Therapeutics INC | $17.71 | 2023 | Accrufer |
| Philips North America LLC | $16.66 | 2024 | (Ck7) Extended Holter |
| Astellas Pharma US INC | $16.02 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.48 | 2024 | Ultomiris |
| Alfasigma USA, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Ferrara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.